Stocktwits on MSN
UNCY stock clocks worst day in a year — analysts keep buy ratings despite ‘5-12 month delay’ in drug approval
The company was seeking approval for the drug to treat hyperphosphatemia in patients with chronic kidney disease on dialysis. ・Both B. Riley and H.C. Wainwright kept their ‘Buy’ ratings on the stock ...
Unicycive Therapeutics is valued at $8/share, with $2/share in cash and the pipeline—primarily OLC—valued at $6/share. OLC targets hyperphosphatemia by reducing pill burden, aiming for improved ...
-- Complete Response Letter relates to deficiencies previously identified at third-party manufacturing vendor -- -- FDA inspection of third-party facility did not occur during the NDA resubmission ...
NEW YORK, April 9, 2026 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Unicycive Therapeutics, Inc. (NASDAQ: UNCY) ...
They talk about how Dr. Gupta’s career positions him in a unique way to make deep impacts, his approach to innovation in the healthcare industry and the impact of technology on patient care. Dr. Gupta ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results